Your browser doesn't support javascript.
loading
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.
Khan, Asim; Cole, Alice; Bhadauria, Naveen; El-Hassan, Munzir; Abdulla, Daud; Axon, Thomas; Fattah, Zozik; Manson, Jessica J; Moreno-Cuesta, Jeronimo; Mukerjee, Dev.
Afiliação
  • Khan A; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK asim.khan7@nhs.net.
  • Cole A; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Bhadauria N; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK.
  • El-Hassan M; Critical Care Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Abdulla D; Pharmacy Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Axon T; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Fattah Z; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Manson JJ; Rheumatology Department, University College London Hospitals NHS Foundation Trust, London, UK.
  • Moreno-Cuesta J; Critical Care Department, North Middlesex University Hospital NHS Trust, London, UK.
  • Mukerjee D; Rheumatology Department, North Middlesex University Hospital NHS Trust, London, UK.
Ann Rheum Dis ; 81(10): e188, 2022 10.
Article em En | MEDLINE | ID: mdl-32732244

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Reumatologia / Doenças Reumáticas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Reumatologia / Doenças Reumáticas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article